登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer
ClinicalTrials.gov 上登记的一项肺癌开放试验,由空军军医大学唐都医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07538193,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Histologically or cytologically confirmed T<sub>any</sub>N2b stage NSCLC (American Joint Committee on Cancer [AJCC] 9th edition). Lymph node status must be confirmed by endobronchial ultrasound (EBUS/EUS) or mediastinoscopy for mediastinal lymph nodes. For left-sided stations 5/6 lymph nodes, parasternal mediastinoscopy is recommended to confirm lymph node status; if mediastinoscopy is not performed, station 5/6 lymph node status is diagnosed based on imaging diagnostic criteria.
入选标准第 3 条
For female patients of non-surgical sterilized or childbearing potential, must agree to use a medically accepted contraceptive method (e.g., intrauterine device, contraceptive pills, or condoms) during the study treatment period and for 3 months after the study treatment period ends; female patients of childbearing potential who are not surgically sterilized must have a negative serum or urine HCG test within 72 hours before the first dose; and must be non-lactating; for male patients with partners of childbearing potential, must agree to use effective contraception during the trial and for 3 months after the last dose of Iparomlimab/Tuvonralimab.
入选标准第 16 条
History of or concurrent other malignancy within the past 5 years (excluding adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical surgery, ductal carcinoma in situ after radical surgery).
排除标准第 2 条
Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
入选标准第 6 条
Absolute neutrophil count ≥1.5×10⁹/L;
入选标准第 8 条
Platelet count ≥100×10⁹/L;
入选标准第 9 条
Hemoglobin ≥90 g/L;
入选标准第 10 条
Serum creatinine ≤1.5×upper limit of normal (ULN) or creatinine clearance (CLcr) ≥40 mL/min calculated by the Cockcroft-Gault formula;
入选标准第 11 条
AST and ALT ≤3×ULN;
入选标准第 13 条
International normalized ratio (INR) or activated partial thromboplastin time (APTT) ≤1.5×ULN, unless the subject is receiving anticoagulant therapy;
入选标准第 14 条
Congenital or acquired immunodeficiency (e.g., HIV-infected individuals).
排除标准第 10 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07538193,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Voluntarily join the study and sign the Informed Consent Form (ICF). ≥18 years old, male or female. Histologically or cytologically confirmed T<sub>any</sub>N2b stage NSCLC (American Joint Committee on Cancer [AJCC] 9th edition). Lymph node status must be confirmed by endobronchial ultrasound (EBUS/EUS) or mediastinoscopy for mediastinal lymph nodes. For left-sided stations 5/6 lymph nodes, parasternal mediastinoscopy is recommended to confirm lymph node status; if mediastinoscopy is not performed, station 5/6 lymph node status is diagnosed based on imaging diagnostic criteria. Based on MDT assessment (which must include a thoracic surgeon specialized in oncology), the primary NSCLC is deemed to be completely resectable (R0). At least one measurable lesion as assessed by the investigator per RECIST v1.1. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1. Adequate organ function meeting the following requirements (no use of any blood components, cell growth factors, etc., within 14 days before the first dose): Absolute neutrophil count ≥1.5×10⁹/L; Platelet count ≥100×10⁹/L; Hemoglobin ≥90 g/L; Serum creatinine ≤1.5×upper limit of normal (ULN) or creatinine clearance (CLcr) ≥40 mL/min calculated by the Cockcroft-Gault formula; Total bilirubin ≤1.5×ULN (patients with Gilbert's syndrome may have ≤3×ULN); AST and ALT ≤3×ULN; International normalized ratio (INR) or activated partial thromboplastin time (APTT) ≤1.5×ULN, unless the subject is receiving anticoagulant therapy; Left ventricular ejection fraction (LVEF) ≥50%. For female patients of non-surgical sterilized or childbearing potential, must agree to use a medically accepted contraceptive method (e.g., intrauterine device, contraceptive pills, or condoms) during the study treatment period and for 3 months after the study treatment period ends; female patients of childbearing potential who are not surgically sterilized must have a negative serum or urine HCG test within 72 hours before the first dose; and must be non-lactating; for male patients with partners of childbearing potential, must agree to use effective contraception during the trial and for 3 months after the last dose of Iparomlimab/Tuvonralimab.排除标准:Exclusion Criteria:
Known presence of EGFR or ALK positive mutations. History of or concurrent other malignancy within the past 5 years (excluding adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical surgery, ductal carcinoma in situ after radical surgery). Prior receipt of any anti-tumor therapy for the current lung cancer (e.g., radiotherapy, chemotherapy, targeted therapy, ablation, or other systemic or local anti-tumor therapies). Current use of immunosuppressants or systemic hormone therapy for immunosuppressive purposes (dose >10 mg/day prednisone or equivalent) and continued use within 2 weeks before enrollment (Note: Inhaled or topical corticosteroids and adrenal replacement steroids are permitted in the absence of active autoimmune disease). Any active autoimmune disease or history of autoimmune disease, including but not limited to: autoimmune hepatitis, interstitial pneumonia, pulmonary fibrosis, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism. Subjects with hypothyroidism controlled by hormone replacement therapy alone are eligible; Subjects with skin diseases not requiring systemic treatment such as vitiligo, psoriasis, alopecia, type 1 diabetes, or childhood asthma that has completely resolved and requires no intervention in adulthood are eligible; Patients with asthma requiring medical intervention with steroids are not eligible. History of allogeneic hematopoietic stem cell transplantation or organ transplantation (except corneal transplantation). Congenital or acquired immunodeficiency (e.g., HIV-infected individuals). Uncontrolled active hepatitis B (defined as positive hepatitis B surface antigen [HBsAg] test at screening with concurrent HBV-DNA test value above the upper limit of normal of the research center's laboratory; subjects with HBV-DNA <500 IU/mL measured within 28 days before study drug administration and who have received standard local antiviral therapy for at least 4 weeks and are willing to continue antiviral therapy during the study may be enrolled). Subjects with active hepatitis C (defined as positive hepatitis C virus antibody [HCsAb] test at screening and positive HCV-RNA). History of severe allergic reactions to other monoclonal antibodies. Vaccination with live vaccine within 30 days before the first dose of study treatment (continuing until 90 days after the last dose of study treatment). Note: Live vaccines include but are not limited to measles, mumps, rubella, varicella/zoster (chickenpox), yellow fever, rabies, BCG, and typhoid vaccines. Inactivated seasonal influenza vaccines, inactivated COVID-19 vaccines, etc., are permitted. Clinically significant cardiovascular or cerebrovascular diseases, including but not limited to: Myocardial infarction or unstable angina pectoris within 6 months before the first dose; Stroke or transient ischemic attack within 6 months before the first dose; Hypertension not controlled with optimal antihypertensive therapy (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg); Clinically significant arrhythmia that has been stable for ≥14 days before the first dose may be enrolled; Congestive heart failure (New York Heart Association [NYHA] functional class III-IV); Myocarditis. Systemic infection or other severe infection requiring intravenous antibiotics for >7 days within 2 weeks before the first study treatment, or unexplained fever >38.5°C during screening or before enrollment (fever due to tumor causes as judged by the investigator is excluded). Any other condition that, in the investigator's judgment, might affect the study results or lead to premature termination of the study, such as alcoholism, drug abuse, other severe diseases (including mental illness) requiring concomitant treatment, severe laboratory abnormalities, or family or social factors, which could affect patient safety.
引自 ClinicalTrials.gov, NCT07538193, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07538193,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。